

erythromycine een plek zou moeten krijgen in de behandeling, dan is dat bij therapieresistente patiënten bij wie het voordeel van het gebruik van erythromycine opweegt tegen de nadelige bijwerkingen. In dat geval is de combinatie met metoclopramide aangewezen.

LITERATUUR

- 1 Wilde AAM, Touw D, Schalekamp T. Geneesmiddelen en het lange QT-interval. Geneesmiddelenbulletin. 2002;36:27-32.
- 2 Sturm A, Holtmann G, Goebell H, et al. Prokinetics in patients with gastroparesis: A systematic analysis. Digestion. 1999;60:422-7.
- 3 Holte K, Kehlet H. Postoperative ileus: Progress towards effective management. Drugs. 2002;62(18):2603-15.
- 4 Tomomasa T, Kuroume T, Arai H, et al. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci. 1986;31:157-61.
- 5 Coulie B, Tack J, Peeters T, et al. Involvement of two different pathways in the motor effects of erythromycin on gastric antrum in humans. Gut. 1998;43:395-400.
- 6 Brunton L, Lazo J, Parker K, red. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11de ed. New York: McGraw-Hill; 2006. p. 984-8.
- 7 Curry JJ, Lander TD, Stringer MD. Review article: erythromycin as a prokinetic agent in infants and children. Aliment Pharmacol Therap. 2001;15:595-603.
- 8 Sarna SK, Soergel KH, Koch TR, et al. Gastrointestinal motor effects of erythromycin in humans. Gastroenterology. 1991;101(6):1488-96.
- 9 Patterson DJ. Prokinetic agents in postgastrectomy patients. Gastroenterol Clin North Am. 1994;23:313-25.
- 10 Bonacini M, Quiason S, Reynolds M, et al. Effect of intravenous erythromycin on post-operative ileus. Am J Gastroenterol. 1993;88:208-11.
- 11 Bungard TJ, Kale-Pradhan PB. Prokinetic agents for the treatment of postoperative ileus in adults: a review of the literature. Pharmacotherapy. 1999;19:416-23.
- 12 Schade RR, Dugas MC, Lhotsky DM, et al. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 1985;30(1):10-5.
- 13 Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2000;14(12):1653-61.
- 14 Janssens J, Peeters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med. 1990;322:1028-31.
- 15 DiBaise JK, Quigley EM. Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis: one center's experience. J Clin Gastroenterol. 1999;28(2):131-4.
- 16 Anthony LB, Krozely MG, Woodward NJ, et al. Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial. J Clin Oncol. 1986; 4(1):98-103.
- 17 Nguyen NQ, Chapman MJ, Fraser RJ, et al. Erythromycin is more effective than metoclopramide in the treatment of feed intolerance in critical illness. Crit Care Med. 2007;35(2):483-9.
- 18 Hawkyard CV, Koerner RJ. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother. 2007;59(3):347-58.
- 19 Dall'Antonia M, Wilks M, Coen PG, et al. Erythromycin for prokinesis: imprudent prescribing? Crit Care. 2006;10:112.
- 20 Reinert RR, Al-Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother. 2002;49(1):61-8.
- 21 Patole S, Rao S, Doherty D. Erythromycin as a prokinetic agent in preterm neonates: a systematic review. Arch Dis Child Fetal Neonat Ed. 2005;90:301-6.
- 22 Mishra A, Friedman HS, Sinha AK. The effects of erythromycin on the electrocardiogram. Chest. 1999;115:983-6.
- 23 Haefeli WE, Schoenenberger RA, Weiss P, et al. Possible risk for cardiac arrhythmia related to intravenous erythromycin. Intensive Care Med. 1992;18:469-73.
- 24 De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002;25(4):263-86.
- 25 de Gier JJ, van Buren HCS, red. Commentaren medicatiebewaking. 2007/2008. Houten: Stichting Health Base; 2007. p. 16-8.
- 26 Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089-96.

Verbetering

In het referaat *Perceptie van inhalatiecorticosteroïde voorspelt therapietrouw* [PW Wetenschappelijk Platform. 2008;2(5):117] staat dat bij de subjectieve rapportage over therapietrouw en bij de objectieve aflevergegevens negatieve correlaties werden gezien met de percepties van de noodzaak en van de zorgen. Deze correlaties waren echter *positief*.